Invention Grant
- Patent Title: GPR40 agonists for the treatment of type II diabetes
-
Application No.: US15228042Application Date: 2016-08-04
-
Publication No.: US09856245B2Publication Date: 2018-01-02
- Inventor: Hui Huang , Sanath Meegalla , Mark R. Player
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Main IPC: C07D413/12
- IPC: C07D413/12 ; C07D413/04 ; C07D275/02 ; C07D261/12 ; C07D261/08 ; C07D231/12 ; C07D249/06 ; C07D401/12 ; C07D401/04 ; C07D233/64 ; C07D333/24 ; C07D409/04
Abstract:
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III) as follows: wherein R1C, R2C, R4C, WC, YC, ZC, and GC, are defined herein.
Public/Granted literature
- US20170044148A1 GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Public/Granted day:2017-02-16
Information query
